key: cord-0874510-46274197
authors: TROSTLE, Megan E.; AGUERO-ROSENFELD, Maria E.; ROMAN, Ashley S.; LIGHTER, Jennifer L.
title: High antibody levels in cord blood from pregnant women vaccinated against COVID-19
date: 2021-09-22
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2021.100481
sha: a9d1b5209af9638a6a3a524f809a3bb871e231c7
doc_id: 874510
cord_uid: 46274197

nan

Current data suggest that transplacental passage of IgG antibodies to SARS-CoV-2 virus occurs following natural infection, 1 and there is emerging evidence that antibody transfer may occur following COVID-19 mRNA vaccination. [2] [3] [4] However, existing studies analyze antibodies to the spike protein (anti-S IgG) alone, which may be present after natural infection or vaccination, and do not include antibodies to the nucleocapsid protein (anti-N IgG), which is only present following natural infection. 6 The objective of this study was to determine the presence of transplacental antibody transmission and levels of detectable antibodies in cord blood in women vaccinated against COVID-19 during pregnancy.

This was an IRB-approved prospective study of pregnant women who received at least one dose of either mRNA COVID-19 vaccine (Pfizer/BioNTech or Moderna) from time of FDA Emergency Use Authorization to June 4, 2021. Eligible women were identified via search of the electronic medical record and recruited via email. Informed consent was obtained electronically. Umbilical cord blood was collected at delivery and analyzed for both anti-N and anti-S IgG.

IgG anti-N antibodies were analyzed using the Abbott SARS-CoV-2 assay on the ARCHITECT i system using chemiluminescent microparticle immunoassay. Results were considered positive if the Index (S/C) was ≥1.4. Anti-S antibodies were tested by Viracor laboratories using Elecsys anti-SARS-CoV-2 assay on the cobas e analyzers. The assay detected predominantly IgG, but also IgA and IgM antibodies providing semiquantitative results in Units/mL. Samples with reactivity ≥0.8 U/mL were considered positive. When the sample result exceeded the upper limit of the analytical measurable interval (250 U/mL), the results were reported as >250 U/mL. Charts were reviewed for maternal demographics, vaccination information, gestational age at delivery, and antibody results. The time interval between administration of the second vaccine injection and delivery was calculated. Descriptive analyses were performed using R Version 4.0.2 (Boston, MA).

Maternal characteristics and vaccination information are in Table 1 . Umbilical cord blood was collected from 36 deliveries. 36 neonates (100%) were positive for anti-S IgG at high titers: 34 with a titer of >250 U/mL and two with titers of 201 U/mL and 249 U/mL, respectively. The median interval from completion of the vaccine series to delivery was 13 weeks, range 5.9-24.9 weeks. The mothers of neonates with cord blood titers <250 U/mL both received their second vaccine dose more than 20 weeks prior to delivery. Three additional women had an interval from vaccination to delivery of over 20 weeks and their neonates had anti-S IgG titers >250 U/mL. Among the 36 samples, 31 were also tested for anti-N IgG and all were negative. All but one of the subjects received both doses of their mRNA vaccines prior to delivery. The neonate born to the woman who received only one dose was still positive for anti-S IgG at a titer of >250 U/mL.

These findings demonstrate transplacental antibody transfer following mRNA COVID-19 vaccination during pregnancy with 100% of cord blood specimens having high levels of anti-S antibodies.

Given the combination of positive anti-S IgG and negative anti-N IgG, the neonatal antibodies were secondary to vertical transfer of antibodies from maternal vaccination rather than natural infection. The moderately high anti-S IgG titers in two women with longer latency between vaccination and delivery suggests that cord blood antibody level may correlate with interval of time from vaccine administration to delivery. Further investigation is needed to determine if vaccination in the second half of pregnancy may confer higher levels of antibody transfer than vaccination earlier in pregnancy.

Our data is novel as it distinguishes between passive immunity from natural infection and immunity from mRNA vaccination by testing anti-N IgG in our cohort of pregnant women. Other studies have evaluated the association of anti-S IgG levels with protection from COVID illness and have determined that high anti-S IgG correlates with immune protection against SARS-CoV-2. 5 The robust cord blood levels observed in our population suggests that the high degree of vertical transmission of these antibodies may protect the infant, at least in the neonatal period. This point is especially important as infants may come into contact after discharge with family members or caretakers who have not received the vaccine (ie, siblings below the age threshold for vaccination). A limitation of this study is that we did not obtain maternal blood to correlate maternal and neonatal antibody levels, though others have found that a correlation may exist. 2 However, with observed high levels in cord blood, such a correlation becomes less clinically relevant.

Recent data suggests only 16.3% of pregnant women have been vaccinated despite evidence of prenatal vaccine safety. 8 Most guidance on the importance on vaccination during pregnancy stems from concern for pregnancy as a risk factor for severe COVID illness in the mother. Our findings add to a growing list of important reasons why women should be advised to receive the COVID vaccine during pregnancy, indicating neonatal benefit and potential protection from COVID illness in the first days of life. Future study should focus on vertical antibody transmission in a larger population and durability of antibody detection during infancy. 

Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios

Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy

Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study

Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. medRxiv

Interim guidelines FOR COVID-19 antibody testing

SARS-CoV-2 Among Infants <90 Days of Age Admitted for Serious Bacterial Infection Evaluation

COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy -Eight Integrated Health Care Organizations, United States